Study points to a strategy for inhibiting hyper-progression of melanoma

Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.

AlidaBio Secures $7.5M to Optimize Epitranscriptomic Research

What You Should Know: – Alida Biosciences (AlidaBio), an innovator in epigenomic research tools, proudly announces the successful completion of a $7.5 million Series A

June 12, 2024

Study finds most patients in TARGET-NASH registry meet revised MASLD criteria – Pharmaceutical Technology

Image credit: Shutterstock/Peakstock Analytics firm Target RWE has published its findings that 99% of participants in TARGET-NASH, a research registry of patients with nonalcoholic fatty

June 12, 2024

Opinion | The Green New Deal for Health Should Not Be Kept a Secret

Cerceo is an academic hospitalist and environmental health advocate. The news is replete with stories of how the health system has been battered over the

February 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.